Humán papillomavírus és méhnyakrák: a tumoros folyamat kialakulásának genetikai háttere.

Translated title of the contribution: Human papillomavirus and cervical cancer: genetic background of the neoplastic process

Z. Szentirmay, J. Cseh, T. Pulay, M. Kásler

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In a 2-year period, 136 HPV positive cytological samples of the cervix uteri were analyzed at the Department of Molecular Pathology, National Institute of Oncology, Hungary. Comparison with the international data obtained from the literature revealed that the Hungarian epidemiological data bore closest resemblance to the European ones except some differences. The HPV18 is rather seldom encountered in this country. Similarly low occurrence was noted only in Japan. However, the 14.1% occurrence rate of HPV58 in Hungary is by far higher than that in any other country in this analysis except Japan where this virus is of similarly high frequency. In Hungary, the incidence of HPV59 is relatively high just like in Central and South America. HPV33 and HPV66 infections occur in a significantly higher number with Hungary than in any of the countries studied. In our study The European type variant of HPV16 (E-V-350G) occurred in 2/10 CIN II-III cases. The authors also compared the various clinico-pathological grouping of HPV types published, and identified several inconsistencies. Viruses considered to have high risk occurred in intact epithelium, CIN I-II-III and carcinoma alike. The general tendency was, however, that certain viruses correlated with specific clinico-pathological entities. At present there is no reason to include the PCR-based HPV typing in the mass screening of cervical cancers. HPV typing and physical state of the virus can reasonable be determined if the cervical cytology is suspect for HPV infection or even control examination after "loop" conisation. Negative cytology completed with negative HPV-DNA test means the lack of cancer risk even in the case of a previously removed CIN or carcinoma. However, a positive HPV test detected after conisation associated with negative cytology finding indicates a risk of 70% of the development of CIN within 2 years.

Original languageHungarian
Pages (from-to)1429-1436
Number of pages8
JournalOrvosi Hetilap
Volume142
Issue number27
Publication statusPublished - Jul 8 2001

Fingerprint

Neoplastic Processes
Hungary
Uterine Cervical Neoplasms
Conization
Viruses
Cell Biology
Japan
Human Papillomavirus DNA Tests
Carcinoma
Central America
Mass Screening
Molecular Pathology
South America
Infection
Cervix Uteri
Epithelium
Polymerase Chain Reaction
Genetic Background
Incidence
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Humán papillomavírus és méhnyakrák : a tumoros folyamat kialakulásának genetikai háttere. / Szentirmay, Z.; Cseh, J.; Pulay, T.; Kásler, M.

In: Orvosi Hetilap, Vol. 142, No. 27, 08.07.2001, p. 1429-1436.

Research output: Contribution to journalArticle

@article{182bfe68360c43ad86a2963a3a902ea6,
title = "Hum{\'a}n papillomav{\'i}rus {\'e}s m{\'e}hnyakr{\'a}k: a tumoros folyamat kialakul{\'a}s{\'a}nak genetikai h{\'a}ttere.",
abstract = "In a 2-year period, 136 HPV positive cytological samples of the cervix uteri were analyzed at the Department of Molecular Pathology, National Institute of Oncology, Hungary. Comparison with the international data obtained from the literature revealed that the Hungarian epidemiological data bore closest resemblance to the European ones except some differences. The HPV18 is rather seldom encountered in this country. Similarly low occurrence was noted only in Japan. However, the 14.1{\%} occurrence rate of HPV58 in Hungary is by far higher than that in any other country in this analysis except Japan where this virus is of similarly high frequency. In Hungary, the incidence of HPV59 is relatively high just like in Central and South America. HPV33 and HPV66 infections occur in a significantly higher number with Hungary than in any of the countries studied. In our study The European type variant of HPV16 (E-V-350G) occurred in 2/10 CIN II-III cases. The authors also compared the various clinico-pathological grouping of HPV types published, and identified several inconsistencies. Viruses considered to have high risk occurred in intact epithelium, CIN I-II-III and carcinoma alike. The general tendency was, however, that certain viruses correlated with specific clinico-pathological entities. At present there is no reason to include the PCR-based HPV typing in the mass screening of cervical cancers. HPV typing and physical state of the virus can reasonable be determined if the cervical cytology is suspect for HPV infection or even control examination after {"}loop{"} conisation. Negative cytology completed with negative HPV-DNA test means the lack of cancer risk even in the case of a previously removed CIN or carcinoma. However, a positive HPV test detected after conisation associated with negative cytology finding indicates a risk of 70{\%} of the development of CIN within 2 years.",
author = "Z. Szentirmay and J. Cseh and T. Pulay and M. K{\'a}sler",
year = "2001",
month = "7",
day = "8",
language = "Hungarian",
volume = "142",
pages = "1429--1436",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "27",

}

TY - JOUR

T1 - Humán papillomavírus és méhnyakrák

T2 - a tumoros folyamat kialakulásának genetikai háttere.

AU - Szentirmay, Z.

AU - Cseh, J.

AU - Pulay, T.

AU - Kásler, M.

PY - 2001/7/8

Y1 - 2001/7/8

N2 - In a 2-year period, 136 HPV positive cytological samples of the cervix uteri were analyzed at the Department of Molecular Pathology, National Institute of Oncology, Hungary. Comparison with the international data obtained from the literature revealed that the Hungarian epidemiological data bore closest resemblance to the European ones except some differences. The HPV18 is rather seldom encountered in this country. Similarly low occurrence was noted only in Japan. However, the 14.1% occurrence rate of HPV58 in Hungary is by far higher than that in any other country in this analysis except Japan where this virus is of similarly high frequency. In Hungary, the incidence of HPV59 is relatively high just like in Central and South America. HPV33 and HPV66 infections occur in a significantly higher number with Hungary than in any of the countries studied. In our study The European type variant of HPV16 (E-V-350G) occurred in 2/10 CIN II-III cases. The authors also compared the various clinico-pathological grouping of HPV types published, and identified several inconsistencies. Viruses considered to have high risk occurred in intact epithelium, CIN I-II-III and carcinoma alike. The general tendency was, however, that certain viruses correlated with specific clinico-pathological entities. At present there is no reason to include the PCR-based HPV typing in the mass screening of cervical cancers. HPV typing and physical state of the virus can reasonable be determined if the cervical cytology is suspect for HPV infection or even control examination after "loop" conisation. Negative cytology completed with negative HPV-DNA test means the lack of cancer risk even in the case of a previously removed CIN or carcinoma. However, a positive HPV test detected after conisation associated with negative cytology finding indicates a risk of 70% of the development of CIN within 2 years.

AB - In a 2-year period, 136 HPV positive cytological samples of the cervix uteri were analyzed at the Department of Molecular Pathology, National Institute of Oncology, Hungary. Comparison with the international data obtained from the literature revealed that the Hungarian epidemiological data bore closest resemblance to the European ones except some differences. The HPV18 is rather seldom encountered in this country. Similarly low occurrence was noted only in Japan. However, the 14.1% occurrence rate of HPV58 in Hungary is by far higher than that in any other country in this analysis except Japan where this virus is of similarly high frequency. In Hungary, the incidence of HPV59 is relatively high just like in Central and South America. HPV33 and HPV66 infections occur in a significantly higher number with Hungary than in any of the countries studied. In our study The European type variant of HPV16 (E-V-350G) occurred in 2/10 CIN II-III cases. The authors also compared the various clinico-pathological grouping of HPV types published, and identified several inconsistencies. Viruses considered to have high risk occurred in intact epithelium, CIN I-II-III and carcinoma alike. The general tendency was, however, that certain viruses correlated with specific clinico-pathological entities. At present there is no reason to include the PCR-based HPV typing in the mass screening of cervical cancers. HPV typing and physical state of the virus can reasonable be determined if the cervical cytology is suspect for HPV infection or even control examination after "loop" conisation. Negative cytology completed with negative HPV-DNA test means the lack of cancer risk even in the case of a previously removed CIN or carcinoma. However, a positive HPV test detected after conisation associated with negative cytology finding indicates a risk of 70% of the development of CIN within 2 years.

UR - http://www.scopus.com/inward/record.url?scp=0035827845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035827845&partnerID=8YFLogxK

M3 - Article

C2 - 11481905

AN - SCOPUS:0035827845

VL - 142

SP - 1429

EP - 1436

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 27

ER -